dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | García Fortes, María |
dc.contributor.author | Alvarez-Larran, Alberto |
dc.contributor.author | Raya, José M. |
dc.contributor.author | Angona, Anna |
dc.contributor.author | Estrada, Natalia |
dc.contributor.author | Fox, Maria Laura |
dc.contributor.author | Hernandez-Boluda, Juan Carlos |
dc.date.accessioned | 2022-09-06T12:05:49Z |
dc.date.available | 2022-09-06T12:05:49Z |
dc.date.issued | 2022-05 |
dc.identifier.citation | García-Fortes M, Hernández-Boluda JC, Álvarez-Larrán A, Raya JM, Angona A, Estrada N, et al. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers. 2022 May;14(9):2331. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/8035 |
dc.description | Comorbidities; Myelofibrosis; Survival |
dc.description.abstract | The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PMF) or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). Hypertension (hazard ratio (HR) = 4.96, p < 0.001), smoking (HR = 5.08, p < 0.001), dyslipidemia (HR = 4.65, p < 0.001) and hepatitis C virus (HCV) (HR = 4.26, p = 0.015) were most adversely associated with OS. Diabetes (HR = 3.01, p < 0.001), pulmonary disease (HR = 3.13, p < 0.001) and renal dysfunction (HR = 1.82, p = 0.037) were also associated with an increased risk of death. Multivariate analysis showed that pulmonary disease (HR = 2.69, p = 0.001), smoking (HR = 3.34, p < 0.001), renal dysfunction (HR = 2.08, p = 0.043) and HCV (HR = 11.49, p = 0.001) had a negative impact on OS. When ruxolitinib exposure was included in the model, the effect of each comorbidity on survival was modified. Therefore, individual comorbidities should be taken into account in determining the survival prognosis for patients with MF. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;14(9) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Comorbiditat |
dc.subject | Mielofibrosi - Prognosi |
dc.subject | Anàlisi de supervivència (Biometria) |
dc.subject.mesh | Primary Myelofibrosis |
dc.subject.mesh | Comorbidity |
dc.subject.mesh | Survival Analysis |
dc.title | Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers14092331 |
dc.subject.decs | mielofibrosis primaria |
dc.subject.decs | comorbilidad |
dc.subject.decs | análisis de supervivencia |
dc.relation.publishversion | https://doi.org/10.3390/cancers14092331 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [García-Fortes M] Hematology Department, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain. Facultad de Medicina, Universidad de Málaga, 29010 Málaga, Spain. [Hernández-Boluda JC] Hematology Department, Hospital Clínico, INCLIVA, 46010 Valencia, Spain. [Álvarez-Larrán A] Hematology Department, Hospital Clínic, 08036 Barcelona, Spain. [Raya JM] Hematology Department, Hospital Universitario de Canarias, 38320 Santa Cruz de Tenerife, Spain. [Angona A] Hematology Department, Hospital del Mar, 08003 Barcelona, Spain. [Estrada N] Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, 08916 Badalona, Spain. [Fox L] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 35565461 |
dc.identifier.wos | 000795385800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |